The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development

• Autorzy: Ucar I. , Ertekin T. , Nisari M. , Ceylan D. , Al O. , Ulger H.
• Języki publikacji: EN

Abstrakty

EN

Background: Interferon beta (IFNβ) was the first proven drug for the treatment of multiple sclerosis (MS). The diagnosis of MS frequently occurs in women at childbearing age (especially in twenties and thirties). Therefore, the pregnancy process is major concern for many women with MS. Data on women exposed to IFNβ during pregnancy are limited. The aim of our study was to investigate the teratogenic potential of IFNβ on embryonic development via embryo culture technique. Recently, this technique has been often used for determining teratogenic effect of pharmacologic drugs and potential teratogens on embryonic development. Materials and methods: In this study, IFNβ was applied to the culture medium and after 48 h of culture effects of IFNβs (1000 IU/IFNβ-1a and 1000 IU/IFNβ-1b) on embryonic development were morphologically investigated. Results: According to morphologic scoring system, total morphologic score, somite number and protein contents were similar between control group and two experimental groups (p > 0.05). On the other hand, yolk sac diameter, crown-rump length and head length were significantly decreased in two experimental groups compared with control group (p < 0.05). Conclusions: Consequently, IFNβ-1a and IFNβ-1b, applied to the culture medium, have no macroscopic teratogenic effect on embryonic development. However, in respect of morphometric measurements, IFNβ-1a and IFNβ-1b have caused growth retardation in embryo. This research related to interferon was the first study using vitro embryo culture technique; thus, in our point of view, future studies which will be performed by using different doses of IFN will contribute to the literature. (Folia Morphol 2016; 75, 2: 257–263)

• Wydawca: -
• Czasopismo: Folia Morphologica
• Rocznik: 2016
• Tom: 75
• Numer: 2
• Opis fizyczny: p.257-263,fig.,ref.

Twórcy

autor

Ucar I.

• Department of Physical Therapy and Rehabilitation, Ahi Evran University, Kırsehir, Turkey

autor

Ertekin T.

• Department of Anatomy, University of Erciyes, Kayseri 38039, Turkey

autor

Nisari M.

• Department of Anatomy, University of Erciyes, Kayseri, Turkey

autor

Ceylan D.

• Genome and Stem Cell Center, University of Erciyes, Kayseri, Turkey

autor

Al O.

• Department of Anatomy, University of Erciyes, Kayseri, Turkey

autor

Ulger H.

• Department of Anatomy, University of Erciyes, Kayseri, Turkey

Bibliografia

• 1. Abreu SL (1985) Interferon in experimental autoimmune encephalomyelitis (EAE) effects of exogenous interferon on the antigen-enhanced adoptive transfer of EAE. Int Archs Allergy Appl Immunol, 76: 302–307. doi: 10.1159/000233711.
• 2. Amato MP, Portaccio E, Ghezzi A, Hakiki B, Zipoli V, Martinelli V, Moiola L, Patti F, La Mantia L, Mancardi GL, Solaro C, Tola MR, Pozzilli C, De Giglio L, Totaro R, Lugaresi A, Di Tommaso V, Paolicelli D, Marrosu MG, Comi G, Pellegrini F, Trojano M (2010) Pregnancy and fetal outcomes after interferon-beta exposure in multiple sclerosis. Neurology, 75: 1794–1802. doi: 10.1212/WNL.0b013e3181fd62bb.
• 3. Beck G, Poindron P, Illinger D, Beck JP, Ebel JP, Falcoff R (1974) Inhibition of steroid inducible tyrosine aminotransferase by mouse and rat interferon in hepatoma tissue culture cells. FEBS Lett, 48: 297–300. doi: 10.1016/0014-5793(74)80490-4.
• 4. Boskovic R, Wide R, Wolpin J, Bauer J, Koren G (2005) The reproductive effects of beta ınterferon therapy in pregnancy. Neurology, 65: 807–811. doi: 10.1212/01.wnl.0000180575.77021.c4.
• 5. Cann AJ (1997) Principles of molecular virology. 2nd Ed. Academic Press, London.
• 6. Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain, 103: 281–300. doi: 10.1093/brain/103.2.281.
• 7. Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY (2010) Fetal growth and development. In: Williams Obstetrics, 23 Ed. McGraw-Hill, New York.
• 8. Dahl J (2008) Multiple Sclerosis and pregnancy: pregnancy, delivery and birth outcome in women with multiple sclerosis. Phd Thesis, University of Bergen, Bergen.
• 9. Damek DM, Shuster EA (1997) Pregnancy and multiple sclerosis. Mayo Clin Proc, 72: 977–989. doi: 10.4065/72.10.977.
• 10. Diaz MO, Bohlander S, Allen G (1996) Nomenclature of the human interferon genes. J Interferon Cytokine Res, 16: 179–180. doi: 10.1089/jir.1996.16.179.
• 11. Ertekin T, Ulger H, Nisari M, Unur E, Şahin U, Elmali F (2011) Effects of Angiostatin on in vitro Embryonic Rat Development. Kafkas Univ Vet Fak Derg, 17: 843–847. doi: 10.9775/kvfd.2011.4637.
• 12. Ferro S, Esposito F, Pretta S, Ragni N (2006) Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. Expert Rew Neurother, 6: 1823–1831. doi: 10.1586/14737175.6.12.1823.
• 13. Ferro S, Pretta S, Ragni N (2004) Multiple sclerosis: management ıssues during pregnancy. Eur J Obster Gynecol Reprod Biol, 115: 3–9. doi: 10.1016/j.ejogrb.2003.10.020.
• 14. Freedman MS, Hughes B, Mikol DD, Bennett R, Cuffel B, Divan V, LaVallee N, AL-Sabbagh A (2008) Efficacy of disease-modifying therapies in relapsing remitting multiple sclerosis: a systematic comparison. Eur Neurol, 60: 1–11. doi: 10.1159/000127972.
• 15. Hardy MP, Owczarek CM, Jermiin LS, Ejdebäck M, Hertzog PJ (2004) Characterization of the type I interferon locus and identification of novel gene. Genomics, 84: 331–345. doi: 10.1016/j.ygeno.2004.03.003.
• 16. Hauser SL, Goodin DS (2005) Multiple sclerosis and other demyelinating diseases. In: Kasper Dl, Braunwald E, Fauci A, Hauser Sl, Longo Dl, Jameson Jl eds. Harrison’s Principles of Internal Medicine. 16th Ed. Mcgraw-Hill Comp, New York, pp. 2461–2470.
• 17. Hellwig K, Haghikia A, Rockhoff M, Gold R (2012) Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord, 5: 247–253. doi: 10.1177/1756285612453192.
• 18. Houtchens MK, Kolb CM (2013) Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol, 260: 1202–1214. doi: 10.1007/s00415-012-6653-9.
• 19. Illinger D, Coupin G, Richards M, Poindron P (1976) Rat interferon inhibits steroid inducible glycerol-3-phosphate dehydrogenase synthesis in a rat glial cell line. FEBS Lett, 64: 391–395. doi: 10.1016/0014-5793(76)80334-1.
• 20. Isaacs A, Lindenmann J (1957) Virus ınterference: the ınterferon. Proc R Soc Lond B Biol Sci, 147: 258–267. doi: 10.1098/rspb.1957.0048.
• 21. Jacobs L, Johnson KP (1994) A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol, 51: 1245–1252. doi: 10.1001/archneur.1994.00540240089022.
• 22. Jacobs L, Malley JA, Freeman A, Ekes R (1981) Intrathecal interferon reduces exacerbations of multiple sclerosis. Science, 214: 1026–1028. doi: 10.1126/science.6171035.
• 23. Kabat EA, Glusman M, Kanaub V (1948) Quantitative estimation of the albumin and gamma globulin in normal and pathologic cerebrospinal fluid by ımmunochemical methods. Am J Med, 4: 653–662. doi: 10.1016/S0002-9343(48)90389-1.
• 24. Kayaalp SO (2005) Rasyonel Tedavi Yönünden Tıbbi Farmakoloji, Cilt 1, Hacettepe-Taş, 11. Baskı. Ankara.
• 25. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP (2001) A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol, 8: 141–148. doi: 10.1046/j.1468-1331.2001.00189.x.
• 26. Loma I, Heyman R (2011) Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol, 9: 409–416. doi: 10.2174/157015911796557911.
• 27. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology, 46: 907–911. doi: 10.1212/WNL.46.4.907.
• 28. New DAT (1978) Whole embryo culture and the study of mammalian embryos during organogenesis. Biol Rev Camb Philos Soc, 53: 81–122. doi: 10.1111/j.1469-185X.1978.tb00993.x.
• 29. New DAT, Stein KF (1964) Cultivation of post-ımplantation mouse and rat embriyos on plasma clots. J Embryol Exp Morphol, 12: 101–111.
• 30. Nisari M, Ulger H (2010) The embryo culture techniques. J Health Sciences, 19: 216–225.
• 31. Nisari M, Ulger H, Unur E, Karaca O, Ertekin T (2014) Effect Of Interleukin 12 (IL-12) on Embryonic Development and Yolk Sac Vascularisation. Bratisl Lek Listy, 115: 532–537. doi: 10.4149/BLL_2014_103.
• 32. Passaquin AC, Coupin G, Poindron P (1986) Rat interferon inhibits catecholamine-inducible synthesis of lactic dehydrogenase in rat glial tumoral C6 cells. J Interferon Res, 6: 71–77. doi: 10.1089/jir.1986.6.71.
• 33. Passaquin AC, Coupin G, Schreier WA, Poindron P, Cole RA, de Vellis J (1989) Interferon inhibits the accumulation of glycerol phosphate dehydrogenase mRNA in oligodendrocytes and C6 cells. Neurochem Res, 14: 987–993. doi: 10.1007/BF00965933.
• 34. Poser S, Poser W (1983) Multiple Sclerosis and gestation. Neurology, 33: 1422–1427. doi: 10.1212/WNL.33.11.1422.
• 35. Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D (2012) Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry, 83: 793–795. doi: 10.1136/jnnp-2012-302848.
• 36. Robinson JF, Verhoef A, van Beelen VA, Pennings JL, Piersma AH (2012) Dose-response analysis of phthalate effects on gene expression in rat whole embryo culture. Toxicol Appl Pharmacol, 264: 32–41. doi: 10.1016/j.taap.2012.07.015.
• 37. Rolak LA (2003) Multiple sclerosis: it’s not the disease you thought it was. Clin Med Res. 1: 57–60.
• 38. Rossi GB (1985) Interferons and cell differentiation. In: Gresser I. ed. Interferon 6. Academic Press, London, pp. 31–50.
• 39. Sadovnick AD, Baird PA (1985) Reproductive counselling for MS patients. Am J Med Genet, 20: 349–354. doi: 10.1002/ajmg.1320200218.
• 40. Sandberg-Wollheim M, Alteri E, Moraga MS, Kornmann G (2011) Pregnancy outcomes in multiple sclerosis following subcutaneous interferon beta-1a therapy. Mult Scler, 17: 423–430. doi: 10.1177/1352458510394610.
• 41. Stewart TA (2003) Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases. Cytokine Growth Factor Rev, 14: 139–154. doi: 10.1016/S1359-6101(02)00088-6.
• 42. Tekinarslan İİ, Unur E, Ulger H, Ekinci N, Ertekin T, Hacıalioğulları M, Arslan S (2011) The Effects of FGF-9 on In Vitro Embryonic Development. Balkan Med J, 28: 18–22. doi: 10.5174/tutfd.2009.02019.2.
• 43. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology, 45: 1277–1285. doi: 10.1212/WNL.45.7.1277.
• 44. Tillman AJB (1950) The effect of pregnancy on multiple sclerosis and its management. Res Publ Assoc Res Nerv Ment Dis, 28: 548–582.
• 45. Torun YA, Ozdemir MA, Ulger H, Nisari M, Akalın H, Patıroglu P, Ozkul Y, Onal M, Karakukcu M (2014) Erythropoietin improves brain development in short-term hypoxia in rat embryo cultures. Brain Dev, 36: 864–869. doi: 10.1016/j.braindev.2014.01.005.
• 46. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain, 112: 133–146. doi: 10.1093/brain/112.1.133.
• 47. Zanon RG, Pierucci A, Alexandre LR (2009) Interferon beta and glatiramer acetate induce proliferation of Schwann cells in vitro. Acta Neurobiol Exp, 69: 146–152.

Identyfikatory

DOI

10.5603/FM.a2015.0099